DIOVAN
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $14,080 | 2 | 1 |
| 2020 | $103,380 | 5 | 0 |
| 2019 | $474,308 | 8 | 0 |
| 2018 | $619,813 | 8 | 0 |
| 2017 | $3,745 | 4 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 22 | 98.6% |
| Consulting Fee | $14,080 | 2 | 1.2% |
| Travel and Lodging | $3,358 | 2 | 0.3% |
| Food and Beverage | $22.04 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER RANDOMIZED NON INTERVENTIONAL PARALLEL DESIGN 4 WEEK DURATION STUDY IN ADULTS TO EVALUATE THE NUMBER AND FREQUENCY OF OUT OF OFFICE BLOOD PRESSURE SELF MEASUREMENTS TO ACCURATELY DIAGNOSE THE PRESENCE OR ABSENCE OF HYPERTENSION | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A 6 WEEK RANDOMIZED MULTICENTER DOUBLE BLIND DOUBLE DUMMY STUDY TO EVALUATE THE DOSE RESPONSE OF VALSARTAN ON BLOOD PRESSURE REDUCTION IN CHILDREN 1 TO 5 YEARS OLD WITH HYPERTENSION WITH OR WITHOUT CHRONIC KIDNEY DISEASE FOLLOWED BY A 20 WEEK OPEN LABEL TITRATION PHASE | Novartis Pharmaceuticals Corporation | $365.00 | 0 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $1.2M
- Novartis Pharma AG $14,080
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 3
- Transactions 27
About DIOVAN
DIOVAN is a drug associated with $1.2M in payments to 3 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2021. In 2021, $14,080 was paid across 2 transactions to 1 doctors.
The most common payment nature for DIOVAN is "Unspecified" ($1.2M, 98.6% of total).
DIOVAN is associated with 2 research studies, including "A MULTICENTER RANDOMIZED NON INTERVENTIONAL PARALLEL DESIGN 4 WEEK DURATION STUDY IN ADULTS TO EVALUATE THE NUMBER AND FREQUENCY OF OUT OF OFFICE BLOOD PRESSURE SELF MEASUREMENTS TO ACCURATELY DIAGNOSE THE PRESENCE OR ABSENCE OF HYPERTENSION" ($1.2M).